Compare TMQ & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMQ | BWAY |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.8M | 547.7M |
| IPO Year | 2012 | 2011 |
| Metric | TMQ | BWAY |
|---|---|---|
| Price | $2.36 | $11.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $6.52 | ★ $19.27 |
| AVG Volume (30 Days) | ★ 1.1M | 102.6K |
| Earning Date | 10-02-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $32.42 |
| Revenue Next Year | N/A | $23.40 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $11.34 |
| 52 Week High | $7.25 | $26.63 |
| Indicator | TMQ | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 18.75 | 33.15 |
| Support Level | N/A | N/A |
| Resistance Level | $3.99 | $14.71 |
| Average True Range (ATR) | 0.12 | 0.49 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 6.11 | 3.20 |
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.